Literature DB >> 22613984

Direct renin inhibition exerts an anti-hypertrophic effect associated with improved mitochondrial function in post-infarction heart failure in diabetic rats.

Rebecca Parodi-Rullan1, Giselle Barreto-Torres, Louis Ruiz, José Casasnovas, Sabzali Javadov.   

Abstract

BACKGROUND: In addition to hypertension control, direct renin inhibition has been shown to exert direct beneficial effects on the heart in post-infarction cardiac remodeling. This study elucidates the possible contribution of mitochondria to the anti-hypertrophic effects of the direct renin inhibitor aliskiren in post-infarction heart failure complicated with diabetes in rats.
METHODS: Diabetes was induced in male Sprague-Dawley rats by a single injection of streptozotocin (IP, 65 mg/kg body weight). After 7 days, the animals were randomly assigned to 4 groups: sham, heart failure, sham+aliskiren, and heart failure+aliskiren. Post-infarction HF was induced by coronary artery ligation for 4 weeks.
RESULTS: showed that heart failure reduced ejection fraction and cardiac output by 41% (P<0.01) and 42% (P<0.05), respectively, compared to sham-operated hearts. Cardiac dysfunction was associated with suppressed state 3 respiration rates and respiratory control index in mitochondria, and increased mitochondrial permeability transition pore (PTP) opening. In addition, heart failure reduced expression of the major mitochondrial sirtuin, SIRT3 and increased acetylation of cyclophilin D, a regulatory component of the PTP. Aliskiren significantly improved cardiac function and abrogated mitochondrial perturbations.
CONCLUSION: Our results demonstrate that aliskiren attenuates post-infarction remodeling which is associated with its beneficial effects on mitochondria.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613984      PMCID: PMC3980674          DOI: 10.1159/000178526

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  38 in total

1.  Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.

Authors:  Yasutomi Higashikuni; Minoru Takaoka; Hiroshi Iwata; Kimie Tanaka; Yasunobu Hirata; Ryozo Nagai; Masataka Sata
Journal:  Hypertens Res       Date:  2011-08-11       Impact factor: 3.872

2.  Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.

Authors:  P Paradis; N Dali-Youcef; F W Paradis; G Thibault; M Nemer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice.

Authors:  Jennifer K Bendall; Alison C Cave; Christophe Heymes; Nicholas Gall; Ajay M Shah
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

4.  Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.

Authors:  Scott D Solomon; Sung Hee Shin; Amil Shah; Hicham Skali; Akshay Desai; Lars Kober; Aldo P Maggioni; Jean L Rouleau; Roxzana Y Kelly; Allen Hester; John J V McMurray; Marc A Pfeffer
Journal:  Eur Heart J       Date:  2011-02-10       Impact factor: 29.983

5.  Identification and characterization of a functional mitochondrial angiotensin system.

Authors:  Peter M Abadir; D Brian Foster; Michael Crow; Carol A Cooke; Jasma J Rucker; Alka Jain; Barbara J Smith; Tyesha N Burks; Ronald D Cohn; Neal S Fedarko; Robert M Carey; Brian O'Rourke; Jeremy D Walston
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-18       Impact factor: 11.205

6.  Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.

Authors:  Yumei Ye; Jinqiao Qian; Alexander C Castillo; Jose Regino Perez-Polo; Yochai Birnbaum
Journal:  Cardiovasc Drugs Ther       Date:  2011-12       Impact factor: 3.727

7.  Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction.

Authors:  T Ide; H Tsutsui; S Hayashidani; D Kang; N Suematsu; K Nakamura; H Utsumi; N Hamasaki; A Takeshita
Journal:  Circ Res       Date:  2001-03-16       Impact factor: 17.367

Review 8.  The renin-angiotensin system and experimental heart failure.

Authors:  K C Wollert; H Drexler
Journal:  Cardiovasc Res       Date:  1999-09       Impact factor: 10.787

9.  Ethanol sensitizes mitochondria to the permeability transition by inhibiting deacetylation of cyclophilin-D mediated by sirtuin-3.

Authors:  Nataly Shulga; John G Pastorino
Journal:  J Cell Sci       Date:  2010-11-09       Impact factor: 5.285

10.  Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy.

Authors:  Angela V Hafner; Jing Dai; Ana P Gomes; Chun-Yang Xiao; Carlos M Palmeira; Anthony Rosenzweig; David A Sinclair
Journal:  Aging (Albany NY)       Date:  2010-12       Impact factor: 5.682

View more
  24 in total

1.  Angiotensin II-preconditioning is associated with increased PKCε/PKCδ ratio and prosurvival kinases in mitochondria.

Authors:  Rebeca E Nuñez; Sabzali Javadov; Nelson Escobales
Journal:  Clin Exp Pharmacol Physiol       Date:  2017-09-20       Impact factor: 2.557

Review 2.  The Role of SIRT3 in Mediating Cardioprotective Effects of RAS Inhibition on Cardiac Ischemia-Reperfusion.

Authors:  Sabzali Javadov; Nelson Escobales
Journal:  J Pharm Pharm Sci       Date:  2015       Impact factor: 2.327

3.  SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts.

Authors:  George A Porter; William R Urciuoli; Paul S Brookes; Sergiy M Nadtochiy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-04-18       Impact factor: 4.733

Review 4.  Mitochondrial angiotensin receptors and cardioprotective pathways.

Authors:  Nelson Escobales; Rebeca E Nuñez; Sabzali Javadov
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-04-12       Impact factor: 4.733

Review 5.  Mitochondrial permeability transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for cardioprotection?

Authors:  Sabzali Javadov; Sehwan Jang; Rebecca Parodi-Rullán; Zaza Khuchua; Andrey V Kuznetsov
Journal:  Cell Mol Life Sci       Date:  2017-04-04       Impact factor: 9.261

6.  The beneficial effects of AMP kinase activation against oxidative stress are associated with prevention of PPARα-cyclophilin D interaction in cardiomyocytes.

Authors:  Giselle Barreto-Torres; Jessica Soto Hernandez; Sehwan Jang; Adlín R Rodríguez-Muñoz; Carlos A Torres-Ramos; Alexei G Basnakian; Sabzali Javadov
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-01-23       Impact factor: 4.733

7.  Fyn kinase regulates translation in mammalian mitochondria.

Authors:  Emine C Koc; Jennifer L Miller-Lee; Hasan Koc
Journal:  Biochim Biophys Acta Gen Subj       Date:  2016-12-07       Impact factor: 3.770

8.  Overexpression of Cardiomyocyte α1A-Adrenergic Receptors Attenuates Postinfarct Remodeling by Inducing Angiogenesis Through Heterocellular Signaling.

Authors:  Xin Zhao; Poornima Balaji; Ronald Pachon; Daniella M Beniamen; Dorothy E Vatner; Robert M Graham; Stephen F Vatner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-03       Impact factor: 8.311

9.  Critical role of angiotensin II type 2 receptors in the control of mitochondrial and cardiac function in angiotensin II-preconditioned rat hearts.

Authors:  Rebeca E Nuñez; Sabzali Javadov; Nelson Escobales
Journal:  Pflugers Arch       Date:  2018-05-10       Impact factor: 3.657

10.  MicroRNA-195 Regulates Metabolism in Failing Myocardium Via Alterations in Sirtuin 3 Expression and Mitochondrial Protein Acetylation.

Authors:  Xiaokan Zhang; Ruiping Ji; Xianghai Liao; Estibaliz Castillero; Peter J Kennel; Danielle L Brunjes; Marcus Franz; Sven Möbius-Winkler; Konstantinos Drosatos; Isaac George; Emily I Chen; Paolo C Colombo; P Christian Schulze
Journal:  Circulation       Date:  2018-01-12       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.